ישראל - עברית - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - תמיסה להזרקה - lutropin alfa 150 iu / 0.48 ml; follitropin alfa 300 iu / 0.48 ml - follitropin alfa

ישראל - עברית - Ministry of Health

merck serono ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 88 mcg/ml - interferon beta-1a

ישראל - עברית - Ministry of Health

medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 10 mg / 1 ml - burosumab

ישראל - עברית - Ministry of Health

medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 20 mg / 1 ml - burosumab

ישראל - עברית - Ministry of Health

medison pharma ltd - burosumab - תמיסה להזרקה - burosumab 30 mg / 1 ml - burosumab

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa pegol - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa pegol 1000 iu/vial

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - faricimab - תמיסה להזרקה - faricimab 120 mg/ml - faricimab

ישראל - עברית - Ministry of Health

sanofi israel ltd - olipudase alfa - olipudase alfa 20 mg/vial - olipudase alfa

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.